Company intelligence / Profile preview

OcuMedic

Mullica Hill, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

OcuMedic has developed a patented, drug‑eluting soft contact lens/clear corneal bandage that provides timed, extended‑release delivery of ophthalmic drugs directly to the eye, targeting indications such as post‑operative inflammation, pain, infection, glaucoma, and dry eye; as of available reports the technology is preparing for entry into the clinic, with no completed human trials yet disclosed.[2][5][6]

Therapeutic areas: Ophthalmology
Modalities: DeviceHydrogel-based drug delivery therapyPolymer-drug conjugate therapy
Industry: Therapeutic Medical Devices

Partnerships

Gelest (investment and supply agreement for novel contact lens drug‑delivery system)[3][5]

Beyond the preview

Go deeper on OcuMedic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OcuMedic.

Explore the full profile